tiprankstipranks
Trending News
More News >
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
US Market

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Compare
6,105 Followers
See the Price Targets and Ratings of:

VRTX Analyst Ratings

Moderate Buy
26Ratings
Moderate Buy
14 Buy
12 Hold
0 Sell
Based on 26 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$512.95
▲( 17.83% Upside)
Based on 26 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $512.95 with a high forecast of $621.00 and a low forecast of $423.00. The average price target represents a 17.83% change from the last price of $435.32.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"401":"$401","622":"$622","456.25":"$456.3","511.5":"$511.5","566.75":"$566.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":621,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$621.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":512.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$512.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":423,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$423.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[401,456.25,511.5,566.75,622],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,498.86,508.2553846153846,517.6507692307692,527.0461538461539,536.4415384615385,545.8369230769231,555.2323076923077,564.6276923076923,574.0230769230769,583.4184615384615,592.8138461538462,602.2092307692308,611.6046153846154,{"y":621,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,498.86,499.94384615384615,501.02769230769235,502.1115384615385,503.1953846153846,504.2792307692308,505.36307692307696,506.4469230769231,507.53076923076924,508.61461538461543,509.6984615384616,510.7823076923077,511.8661538461539,{"y":512.95,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,498.86,493.0246153846154,487.1892307692308,481.3538461538462,475.51846153846157,469.68307692307695,463.84769230769234,458.0123076923077,452.17692307692306,446.34153846153845,440.50615384615384,434.6707692307692,428.8353846153846,{"y":423,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":402.14,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455.34,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":471.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":505.78,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":495.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":471.12,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":465.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":461.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":479.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$621.00Average Price Target$512.95Lowest Price Target$423.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Scotiabank Analyst forecast on VRTX
Greg HarrisonScotiabank
Scotiabank
$442
Hold
1.53%
Upside
Reiterated
05/21/25
Bank of America Securities Analyst forecast on VRTX
Tazeen AhmadBank of America Securities
Bank of America Securities
$567
Buy
30.25%
Upside
Reiterated
05/21/25
Evercore ISI Analyst forecast on VRTX
Liisa BaykoEvercore ISI
Evercore ISI
$510
Buy
17.16%
Upside
Reiterated
05/20/25
BMO Capital Analyst forecast on VRTX
Evan SeigermanBMO Capital
BMO Capital
$557
Buy
27.95%
Upside
Reiterated
05/16/25
Stifel Nicolaus Analyst forecast on VRTX
Paul MatteisStifel Nicolaus
Stifel Nicolaus
$494
Hold
13.48%
Upside
Reiterated
05/14/25
Barclays Analyst forecast on VRTX
Gena WangBarclays
Barclays
$467$499
Hold
14.63%
Upside
Reiterated
05/07/25
Truist Financial Analyst forecast on VRTX
Joon LeeTruist Financial
Truist Financial
Buy
Reiterated
05/06/25
Leerink Partners Analyst forecast on VRTX
David RisingerLeerink Partners
Leerink Partners
$550$503
Hold
15.55%
Upside
Downgraded
05/06/25
Canaccord Genuity Analyst forecast on VRTX
Whitney IjemCanaccord Genuity
Canaccord Genuity
$424
Hold
-2.60%
Downside
Reiterated
05/06/25
Goldman Sachs Analyst forecast on VRTX
Salveen RichterGoldman Sachs
Goldman Sachs
$617$621
Buy
42.65%
Upside
Reiterated
05/06/25
J.P. Morgan Analyst forecast on VRTX
Jessica FyeJ.P. Morgan
J.P. Morgan
$512$515
Buy
18.30%
Upside
Reiterated
05/06/25
Morgan Stanley Analyst forecast on VRTX
Terence FlynnMorgan Stanley
Morgan Stanley
$462$464
Hold
6.59%
Upside
Reiterated
05/06/25
Wolfe Research Analyst forecast on VRTX
Andy ChenWolfe Research
Wolfe Research
Hold
Downgraded
05/06/25
William Blair Analyst forecast on VRTX
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/06/25
Citi
$575
Buy
32.09%
Upside
Reiterated
05/06/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Scotiabank Analyst forecast on VRTX
Greg HarrisonScotiabank
Scotiabank
$442
Hold
1.53%
Upside
Reiterated
05/21/25
Bank of America Securities Analyst forecast on VRTX
Tazeen AhmadBank of America Securities
Bank of America Securities
$567
Buy
30.25%
Upside
Reiterated
05/21/25
Evercore ISI Analyst forecast on VRTX
Liisa BaykoEvercore ISI
Evercore ISI
$510
Buy
17.16%
Upside
Reiterated
05/20/25
BMO Capital Analyst forecast on VRTX
Evan SeigermanBMO Capital
BMO Capital
$557
Buy
27.95%
Upside
Reiterated
05/16/25
Stifel Nicolaus Analyst forecast on VRTX
Paul MatteisStifel Nicolaus
Stifel Nicolaus
$494
Hold
13.48%
Upside
Reiterated
05/14/25
Barclays Analyst forecast on VRTX
Gena WangBarclays
Barclays
$467$499
Hold
14.63%
Upside
Reiterated
05/07/25
Truist Financial Analyst forecast on VRTX
Joon LeeTruist Financial
Truist Financial
Buy
Reiterated
05/06/25
Leerink Partners Analyst forecast on VRTX
David RisingerLeerink Partners
Leerink Partners
$550$503
Hold
15.55%
Upside
Downgraded
05/06/25
Canaccord Genuity Analyst forecast on VRTX
Whitney IjemCanaccord Genuity
Canaccord Genuity
$424
Hold
-2.60%
Downside
Reiterated
05/06/25
Goldman Sachs Analyst forecast on VRTX
Salveen RichterGoldman Sachs
Goldman Sachs
$617$621
Buy
42.65%
Upside
Reiterated
05/06/25
J.P. Morgan Analyst forecast on VRTX
Jessica FyeJ.P. Morgan
J.P. Morgan
$512$515
Buy
18.30%
Upside
Reiterated
05/06/25
Morgan Stanley Analyst forecast on VRTX
Terence FlynnMorgan Stanley
Morgan Stanley
$462$464
Hold
6.59%
Upside
Reiterated
05/06/25
Wolfe Research Analyst forecast on VRTX
Andy ChenWolfe Research
Wolfe Research
Hold
Downgraded
05/06/25
William Blair Analyst forecast on VRTX
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/06/25
Citi
$575
Buy
32.09%
Upside
Reiterated
05/06/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

1 Month
xxx
Success Rate
17/26 ratings generated profit
65%
Average Return
+1.78%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.38% of your transactions generating a profit, with an average return of +1.78% per trade.
3 Months
xxx
Success Rate
22/31 ratings generated profit
71%
Average Return
+8.39%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.97% of your transactions generating a profit, with an average return of +8.39% per trade.
1 Year
Brian SkorneyRobert W. Baird
Success Rate
13/17 ratings generated profit
76%
Average Return
+12.31%
reiterated a sell rating 4 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +12.31% per trade.
2 Years
xxx
Success Rate
28/31 ratings generated profit
90%
Average Return
+30.12%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.32% of your transactions generating a profit, with an average return of +30.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
1
1
0
0
0
Buy
47
51
45
32
29
Hold
33
36
31
22
23
Sell
5
3
2
0
0
Strong Sell
0
0
0
0
0
total
86
91
78
54
52
In the current month, VRTX has received 29 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the past 3 months is 512.95.
Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $4.29 with a range of $3.89 to $4.68. The previous quarter’s EPS was $4.06. VRTX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.28% of the time in the same period. In the last calendar year VRTX has Outperformed its overall industry.
Next quarter’s earnings estimate for VRTX is $4.29 with a range of $3.89 to $4.68. The previous quarter’s EPS was $4.06. VRTX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.28% of the time in the same period. In the last calendar year VRTX has Outperformed its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $2.90B with a range of $2.75B to $2.97B. The previous quarter’s sales results were $2.75B. VRTX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.44% of the time in the same period. In the last calendar year VRTX has Outperformed its overall industry.
Next quarter’s sales forecast for VRTX is $2.90B with a range of $2.75B to $2.97B. The previous quarter’s sales results were $2.75B. VRTX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.44% of the time in the same period. In the last calendar year VRTX has Outperformed its overall industry.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 512.95.
    What is VRTX’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals has 17.83% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VRTX a Buy, Sell or Hold?
          Vertex Pharmaceuticals has a consensus rating of Moderate Buy which is based on 14 buy ratings, 12 hold ratings and 0 sell ratings.
            What is Vertex Pharmaceuticals’s price target?
            The average price target for Vertex Pharmaceuticals is 512.95. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $621.00 ,the lowest forecast is $423.00. The average price target represents 17.83% Increase from the current price of $435.32.
              What do analysts say about Vertex Pharmaceuticals?
              Vertex Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Streets Analysts.
                How can I buy shares of VRTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis